Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study

16215STML-ELA-0422-NCT06492616Open (affiliates only)Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 StudySTML-ELA-0422NCT06492616IndustrialAdultTreatmentIIIOtherKhoury, KatiaGeorgetown University Medical Center : Julie Castle, Antonella Novielli; Lombardi Comprehensive Cancer Center : Julie Castle, Antonella NovielliBreastOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS7263Julie CastleJulie Castle+1 202-687-2209bickmorj@georgetown.eduClinical Research Nurse 7311Antonella NovielliAntonella Novielli+1 202-784-3923+1 202-687-3372noviella@georgetown.eduClinical Research Nurse 2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>